This study is testing a new treatment for a type of cancer called **B-cell Non-Hodgkin Lymphoma** (B-NHL). This cancer affects a part of the immune system called B-cells. The study focuses on patients whose cancer has come back or didn't respond to previous treatments. It tests how safe and effective a drug called **loncastuximab tesirine** is when combined with other cancer drugs like **polatuzumab vedotin, glofitamab,** and **mosunetuzumab**. Participants will be monitored for safety and the best dosage will be determined. The study has a **Screening Period** (up to 28 days), a **Treatment Period** (21-day cycles), and a **Follow-up Period** (visits every 12 weeks for up to 2 years).

• The study lasts up to 1 year of treatment with follow-up visits every 12 weeks for 2 years.
• Participants must have tried at least two previous treatments that didn't work.
• There are strict rules about health conditions; pregnant or breastfeeding women cannot participate.